Displaced populations face significant barriers to oncology care, with 2025 research indicating that cancer prevalence among refugees ranges from 0.5% to 13.3% across various host nations. According to a 2025 systematic review of 561,850 refugees, these individuals frequently encounter fragmented medical records, late-stage diagnoses, and limited access to specialized treatment, necessitating a shift toward integrating oncology services into national health systems rather than relying on short-term humanitarian aid.
Why Is Cancer Often Diagnosed at Advanced Stages in Refugee Populations?
Late-stage cancer presentation among refugees is primarily driven by systemic barriers that delay medical intervention. Data from studies on Syrian refugees in Turkey show that between 68% and 76.4% of patients present with stage III or IV disease at the time of diagnosis. According to the 2025 systematic review, this trend stems from a combination of financial hardship, language barriers, and a lack of documentation. When displaced individuals prioritize immediate needs like food and shelter, medical symptoms—even severe ones—often go unaddressed until they become acute. The absence of streamlined referral pathways further exacerbates these delays, as patients struggle to move through complex administrative systems without stable housing or legal status.
How Does Funding Instability Impact Treatment Continuity?
Cancer care is time-sensitive, yet humanitarian funding is often structured around short-term emergency cycles that fail to cover multi-year treatment protocols. Evidence from the UNHCR Exceptional Care Committees in Jordan highlights the consequences of this mismatch. Between 2016 and 2017, only 40% of 289 cancer-treatment applications were approved and funded, with many denials attributed to poor prognosis in resource-constrained settings. According to the analysis of these committee records, the reliance on emergency funding creates a “treatment lottery” where patients may lose access to chemotherapy or radiotherapy simply because their care plan extends beyond the current grant cycle. This fragmentation often results in incomplete treatment courses, which significantly lowers survival rates.
What Are the Emerging Future Trends in Refugee Oncology?
To address these inequities, global health policy is shifting toward the integration of oncology into universal health coverage plans. Experts suggest that future responses must prioritize three key areas to move beyond reactive aid:
- Interoperable Medical Records: Developing digital health passports that allow refugees to carry their pathology and treatment history across borders, preventing the loss of critical diagnostic data.
- National Health System Integration: Moving away from parallel, NGO-led health programs in favor of embedding refugee care into existing national oncology infrastructure to increase capacity for both refugees and host communities.
- Sustainable Financing Models: Establishing long-term partnerships between governments, private industry, and international insurers to fund the multi-year costs of cancer care, which are currently unsupported by traditional humanitarian budgets.
Frequently Asked Questions
Who is considered a refugee?
A refugee is an individual who has fled their home country due to a well-founded fear of persecution based on race, religion, nationality, political opinion, or social group membership, as defined by the 1951 Refugee Convention.
Why is cancer surveillance limited in refugee settings?
Surveillance is hindered by the loss of medical records during displacement and a lack of access to consistent cancer registries. These factors lead to an under-documented burden of disease in many host countries.
Can children with cancer receive specialized care as refugees?
While specialized paediatric oncology requires complex multidisciplinary support, refugee children often face worse outcomes than non-refugee peers. Success depends on providing families with logistical support, including transportation, nutrition, and psychosocial aid, alongside clinical treatment.
Are you a healthcare professional or policy advocate working with displaced communities? Share your experiences in the comments below, or subscribe to our newsletter for the latest updates on global oncology health policy.
Worth a look